Your prediction
Pluristem Therapeutics Inc. Stock
Our community identified positive and negative aspects for Pluristem Therapeutics Inc. stock for the coming years. 1 users see the criterium "Revenue growth" as a plus for the Pluristem Therapeutics Inc. stock. On the other hand our users think that "EBIT growth" could be a problem in the future.
Pros and Cons of Pluristem Therapeutics Inc. in the next few years
Pros
?
M***** P*******
?
B****
?
G***** c******* t* c**********
Cons
?
S********** s********
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Pluristem Therapeutics Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Pluristem Therapeutics Inc. | - | - | - | - | - | - | - |
| Enlivex Therapeutics Ltd. | -5.190% | 14.925% | -58.152% | -38.889% | -31.250% | -83.958% | - |
| Oramed Pharmaceuticals | 0.050% | 2.244% | -16.207% | -8.379% | 3.355% | -75.344% | -32.976% |
| Galmed Pharmaceuticals Ltd. | -1.100% | -6.522% | 13.907% | 23.741% | -21.101% | - | - |